Deals
Pfizer Said to Plan Raising AstraZeneca Bid a Second Time
This article is for subscribers only.
Pfizer Inc. is planning to sweeten its bid for U.K. rival AstraZeneca Plc for a second time, people with knowledge of the matter said.
Pfizer and its advisers are crafting a new offer that would increase the value modestly above the current 50 pounds-a-share (about $84) level while bumping the cash portion, said two of the people, who asked not to be identified discussing private information. Pfizer will probably wait until after U.K. government hearings to raise its bid, they said.